Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
Glenda E GrayLinda-Gail BekkerFatima LaherMookho MalahlehaMary AllenZoe MoodieNicole GrunenbergYunda HuangDoug GroveBrittany PrigmoreJia J KeeDavid BenkeserJohn HuralCraig InnesErica LazarusGraeme MeintjesNivashnee NaickerDishiki KalonjiMaphoshane NchabelengModulakgotla SebeNishanta SinghPhilip KotzeSheetal KassimThozama DubulaVimla NaickerWilliam BrumskineCleon N NcayiyaAmy M WardNigel GarrettGirisha KistnasamiZakir GaffoorPearl SelepePhilisiwe B MakhobaMatsontso P MathebulaPamela MdaTania AdonisKatlego S MapetlaBontle ModibediTricia PhilipGladys KobaneCarter BentleyShelly RamirezSimbarashe TakuvaMegan JonesMpho SikhosanaMillicent AtujunaMichele AndrasikNima S HejaziAdrian PurenLubbe WiesnerSanjay PhogatCarlos Diaz GranadosMarguerite KoutsoukosOlivier Van Der MeerenSusan W BarnettNiranjan Kanesa-ThasanJames G KublinM Juliana McElrathPeter B GilbertHolly JanesLawrence Coreynull nullPublished in: The New England journal of medicine (2021)
The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.).